BACKGROUND: Pulmonary toxicity is a well-known complication observed with several anticancer drugs. Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including non-small cell lung cancer (NSCLC), rarely causes infiltrative pneumonitis. The exact mechanism by which docetaxel develops this side effect is not well understood; probably it is produced by type I and IV hypersensitivity responses. Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. After 3 courses of chemotherapy, restaging computed tomography (CT) of the chest revealed bilateral diffuse ground-glass opacities with a peribronchial distribution possibly indicative of hypersensitivity pneumonitis. No evidence of pulmonary embolus or pleural effusion was found. Fiberoptic bronchoscopy showed normal bronchi without lymphangitis; biopsies showed interstitial fibrosis without tumor cells. Bronchial tissue laboratory tests for fungi or bacilli were negative. No malignant cells were found at bronchoalveolar lavage. The patients were given high-dose corticosteroid therapy with prednisone 0.7 mg per kilogram per day. RESULTS: After 1 month of therapy, contrast-enhanced chest CT showed complete disappearance of the pulmonary changes in both patients. Spirometry and blood gas analysis revealed complete recovery of pulmonary function. The patients continued their oncological follow-up program. CONCLUSIONS: Pulmonary injury is a rare adverse event during docetaxel chemotherapy. Prompt treatment with high-dose corticosteroids is needed to avoid worsening of respiratory performance.
BACKGROUND:Pulmonary toxicity is a well-known complication observed with several anticancer drugs. Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including non-small cell lung cancer (NSCLC), rarely causes infiltrative pneumonitis. The exact mechanism by which docetaxel develops this side effect is not well understood; probably it is produced by type I and IV hypersensitivity responses. Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. After 3 courses of chemotherapy, restaging computed tomography (CT) of the chest revealed bilateral diffuse ground-glass opacities with a peribronchial distribution possibly indicative of hypersensitivity pneumonitis. No evidence of pulmonary embolus or pleural effusion was found. Fiberoptic bronchoscopy showed normal bronchi without lymphangitis; biopsies showed interstitial fibrosis without tumor cells. Bronchial tissue laboratory tests for fungi or bacilli were negative. No malignant cells were found at bronchoalveolar lavage. The patients were given high-dose corticosteroid therapy with prednisone 0.7 mg per kilogram per day. RESULTS: After 1 month of therapy, contrast-enhanced chest CT showed complete disappearance of the pulmonary changes in both patients. Spirometry and blood gas analysis revealed complete recovery of pulmonary function. The patients continued their oncological follow-up program. CONCLUSIONS:Pulmonary injury is a rare adverse event during docetaxel chemotherapy. Prompt treatment with high-dose corticosteroids is needed to avoid worsening of respiratory performance.
Authors: Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre Journal: Expert Rev Anticancer Ther Date: 2018-07-23 Impact factor: 4.512
Authors: Gerald Falchook; Jeffrey Infante; Hendrik-Tobias Arkenau; Manish R Patel; Emma Dean; Erkut Borazanci; Andrew Brenner; Natalie Cook; Juanita Lopez; Shubham Pant; Arthur Frankel; Peter Schmid; Kathleen Moore; William McCulloch; Katharine Grimmer; Marie O'Farrell; George Kemble; Howard Burris Journal: EClinicalMedicine Date: 2021-03-30
Authors: Martin H Cherk; David P Nadebaum; Thomas W Barber; Paul Beech; Andrew Haydon; Kenneth S Yap Journal: J Med Imaging Radiat Oncol Date: 2022-02-22 Impact factor: 1.667